The Neurosyphilis Market is projected to reach USD 1,623.5 Million by 2030 at 7.1% CAGR during the forecast period 2022-2030.
Neurosyphilis is the infection of spinal cord and brain. It is most common in an individual who have untreated syphilis for long period of time. This is mainly caused due to bacteria called Treponema pallidum. This is the bacteria which causes syphilis. After getting infected with syphilis for the first time, there are chances of neurosyphilis after 10-20 years later. The major symptoms of neurosyphilis are blindness, abnormal walk, confusion, depression, dementia, headache, irritability, incontinence, poor concentration, numbness in the toes, feet, or legs, seizures, tremors, stiff neck, visual disturbances, and weakness. There are possibility of no symptoms of neurosyphilis. Out of all types of neurosyphilis, asymptomatic neurosyphilis is the most common type.
Considering the market scenario of neurosyphilis, increasing funding for research, clinical trials, and new product development are driving the growth for the market. Government and companies are investing large amount of money to derive effective cure for neurosyphilis. Adoption of technologically advanced diagnostic medical devices are another important driver for the market. Some other factors like increasing awareness, rising demand from emerging markets, government support to improve public healthcare, and changing healthcare practices are also major factors for the market growth.
FIGURE 1 GLOBAL NEUROSYPHILIS MARKET SHARE BY END USER, 2016 (%)
Sources: National Institute of Neurological Disorders and Stroke, National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine, Directorate of Industries, Annual report, White paper, Company Presentation
Key players for global neurosyphilis market:
Some of the key players in this market are: Abbott (US), Bayer AG (Germany), Eli Lilly and Company (US), GlaxoSmithKline plc. (UK), Novartis AG (Switzerland), Pfizer Inc. (US), Sanofi (France), and others.
Neurosyphilis Market Segments:
Global neurosyphilis market has been segmented on the basis of type which comprise asymptomatic neurosyphilis, meningeal neurosyphilis, meningovascular neurosyphilis, general paresis, tabes dorsalis, and others.
On the basis of diagnosis, the neurosyphilis market is segmented into physical exam, blood test, spinal tap, imaging tests, and others. Blood test is further subsegmented into Venereal disease research laboratory (VDRL) test, Fluorescent treponemal antibody absorption (FTA-ABS), Rapid plasma reagin (RPR), Treponema pallidum particle agglutination assay (TPPA), and others. Imaging tests is further sub-segmented into Computed Tomography (CT), X-rays, Magnetic resonance imaging (MRI), and others.
On the basis of treatments, the market has been segmented into antibiotic penicillin, antibiotics probenecid, ceftriaxone and others. Antibiotic penicillin is further sub-segmented into Injection and oral.
On the basis of end user, it is segmented into hospital and clinics, medical research centers, academic institutes, and others.
Regional Analysis of Neurosyphilis Market:
Considering the global scenario of the market, the Americas are holding the largest market for neurosyphilis. The Americas mainly include North America and Latin America, out of which North America is holding majority of market share of this region. US is the top revenue generating market in North America and is one of the important markets for global neurosyphilis. Various factors are leading the market growth such as availability of funding for research and clinical trials, and advanced diagnostic and treatment options. Latin America neurosyphilis market is also growing significantly and mainly includes Brazil, Argentina and Chile. Europe is the second largest and one of the important markets for neurosyphilis. Increasing cases of neurosyphilis is a key driving factor for this market. Europe is mainly divided into Eastern Europe and Western Europe. More developed western European countries like Germany, UK and France are dominating this market while East European region is also growing significantly. Asia Pacific region is showing the fastest growth rate in global neurosyphilis market due to some major factors such as increasing awareness of the disorder and related care, increasing investment in research, and rapidly improving healthcare facilities. Japan is holding major market share while China neurosyphilis market is expected to have fastest growth in this region. Governments of different Asia nations are taking various initiatives to increase awareness of this disease that plays important role in the growth of this market. Middle East & Africa is expected to have a limited growth due to lack of knowledge of disease, traditional healthcare practices etc. Middle East region is dominating this market due to some major factors like developed healthcare facilities and government support to improve public health.
|Market Size||2030: USD 1,623.5 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||By Type, Diagnosis, Treatment, End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Abbott (US), Bayer AG (Germany), Eli Lilly and Company (US), GlaxoSmithKline plc. (UK), Novartis AG (Switzerland), Pfizer Inc. (US), Sanofi (France)|
|Key Market Opportunities||
|Key Market Drivers||Clinical trials, funding for research, and adoption of advanced diagnostic devices|
neurosyphilis market is expected to exhibit a CAGR of 7.1% from 2022 to 2030.
neurosyphilis market is predicted to touch USD 1,623.5 Million by 2030.
Clinical trials, funding for research, and adoption of advanced diagnostic devices are major drivers of the global neurosyphilis market.
North America can dominate the global neurosyphilis market.
The Middle East & Africa (MEA) can showcase the lowest growth rate in the global neurosyphilis market.
Bayer AG, Novartis AG, Abbott, GlaxoSmithKline plc., Sanofi, Pfizer Inc., and Eli Lilly and Company are notable players of the global neurosyphilis market.